WO2005070003A2 - Abuse potential reduction in abusable substance dosage form - Google Patents
Abuse potential reduction in abusable substance dosage formInfo
- Publication number
- WO2005070003A2 WO2005070003A2 PCT/US2005/002246 US2005002246W WO2005070003A2 WO 2005070003 A2 WO2005070003 A2 WO 2005070003A2 US 2005002246 W US2005002246 W US 2005002246W WO 2005070003 A2 WO2005070003 A2 WO 2005070003A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substance
- abuse
- abusable
- patch
- amount
- Prior art date
Links
- 239000000126 substance Substances 0.000 title claims abstract description 81
- 230000009467 reduction Effects 0.000 title description 4
- 239000002552 dosage form Substances 0.000 title description 3
- 201000009032 substance abuse Diseases 0.000 claims abstract description 66
- 238000000034 method Methods 0.000 claims abstract description 27
- 231100000736 substance abuse Toxicity 0.000 claims abstract description 7
- 208000011117 substance-related disease Diseases 0.000 claims abstract description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 33
- 239000011230 binding agent Substances 0.000 claims description 24
- 239000005557 antagonist Substances 0.000 claims description 22
- 239000002085 irritant Substances 0.000 claims description 20
- 231100000021 irritant Toxicity 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 12
- 239000012528 membrane Substances 0.000 claims description 11
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 229960002428 fentanyl Drugs 0.000 claims description 9
- 239000000853 adhesive Substances 0.000 claims description 8
- 230000001070 adhesive effect Effects 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000010410 layer Substances 0.000 description 24
- 239000000463 material Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 13
- 229960004207 fentanyl citrate Drugs 0.000 description 11
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 11
- 239000002250 absorbent Substances 0.000 description 10
- 230000002745 absorbent Effects 0.000 description 10
- 210000004379 membrane Anatomy 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000002798 spectrophotometry method Methods 0.000 description 6
- 238000000926 separation method Methods 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000000274 adsorptive effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000383 hazardous chemical Substances 0.000 description 2
- 239000004081 narcotic agent Substances 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 230000008275 binding mechanism Effects 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940099191 duragesic Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 229960003086 naltrexone Drugs 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A62—LIFE-SAVING; FIRE-FIGHTING
- A62D—CHEMICAL MEANS FOR EXTINGUISHING FIRES OR FOR COMBATING OR PROTECTING AGAINST HARMFUL CHEMICAL AGENTS; CHEMICAL MATERIALS FOR USE IN BREATHING APPARATUS
- A62D3/00—Processes for making harmful chemical substances harmless or less harmful, by effecting a chemical change in the substances
- A62D3/30—Processes for making harmful chemical substances harmless or less harmful, by effecting a chemical change in the substances by reacting with chemical agents
- A62D3/33—Processes for making harmful chemical substances harmless or less harmful, by effecting a chemical change in the substances by reacting with chemical agents by chemical fixing the harmful substance, e.g. by chelation or complexation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A62—LIFE-SAVING; FIRE-FIGHTING
- A62D—CHEMICAL MEANS FOR EXTINGUISHING FIRES OR FOR COMBATING OR PROTECTING AGAINST HARMFUL CHEMICAL AGENTS; CHEMICAL MATERIALS FOR USE IN BREATHING APPARATUS
- A62D3/00—Processes for making harmful chemical substances harmless or less harmful, by effecting a chemical change in the substances
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
- B09B—DISPOSAL OF SOLID WASTE NOT OTHERWISE PROVIDED FOR
- B09B3/00—Destroying solid waste or transforming solid waste into something useful or harmless
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
- B09B—DISPOSAL OF SOLID WASTE NOT OTHERWISE PROVIDED FOR
- B09B3/00—Destroying solid waste or transforming solid waste into something useful or harmless
- B09B3/0075—Disposal of medical waste
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D25/00—Details of other kinds or types of rigid or semi-rigid containers
- B65D25/14—Linings or internal coatings
-
- A—HUMAN NECESSITIES
- A62—LIFE-SAVING; FIRE-FIGHTING
- A62D—CHEMICAL MEANS FOR EXTINGUISHING FIRES OR FOR COMBATING OR PROTECTING AGAINST HARMFUL CHEMICAL AGENTS; CHEMICAL MATERIALS FOR USE IN BREATHING APPARATUS
- A62D2101/00—Harmful chemical substances made harmless, or less harmful, by effecting chemical change
- A62D2101/20—Organic substances
- A62D2101/26—Organic substances containing nitrogen or phosphorus
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
- B09B—DISPOSAL OF SOLID WASTE NOT OTHERWISE PROVIDED FOR
- B09B2101/00—Type of solid waste
- B09B2101/65—Medical waste
- B09B2101/68—Transdermal patches
Definitions
- the present invention relates generally to transdermal dosage forms for administering substances of a class typically subject to abuse to the body of a patient and, particularly, to reducing the potential for abuse related to the use of such devices. More particularly, the invention involves the use of binding agents to immobilize and prevent extraction of amounts of abusable substances remaining in transdermal patch devices after initial therapeutic transdermal administration to a patient. Other techniques are also included.
- II. Related Art The temptation and potential for abuse by ingestion, injection, etc. of narcotics and other controlled substances is well known.
- That document discloses the combination of the drug with a co-formulated antagonist agent that is present in a form not releasable in the dosage form, but one which releases to prevent abuse of the composition by certain other routes of administration.
- the co-formulated antagonist does not penetrate transdermally, but would be co-extracted during an attempt to extract the abusable material as by using solvents or by removing and ingesting the combination.
- One disadvantage to this apaproach resides in the shelf-life complications associated with co- formulation of two active pharmaceutical ingredients in a transdermal patch. Another significant limitation to this approach is that a used patch can still be abused with transdermal wear.
- a system and method for reducing the potential for substance abuse in skin-worn transdermal patch devices containing residual amounts of abusable substances after removal of the patch devices from a first user involves the use of a separate anti-abuse substance which may be a binding agent which immobilizes and deactivates the abusable substance on contact thereby reducing the potential for abuse.
- the anti-abuse substance may also contain an antagonist or irritant compound or, in certain cases, consist of an antagonist or irritant compound as will be described below.
- the abuse prevention system of the present invention is generally associated with the removal and disposal of skin-worn patches and may take any of several forms .
- Preferred binding compositions include those binding agents which may be absorbents for the abusable material. These agents immobilize the abusable substance and precludes future separation by normally available means.
- Activated carbon has been found to be a material particularly suitable for the adsorption of opioid compounds including synthetic opioids such as fentanyl. Thus, contacting these compounds with a suitable binding agent has been found to thereafter prevent extraction by normal solvents and other means readily available to prospective abusers.
- One form of a system for reducing potential substance abuse in skin-worn transdermal patch devices containing residual amounts of abusable substances in accordance with the present invention includes a disposable container or pouch which has an opening configured to receive a skin-worn patch device after removal from a patient at the conclusion of the normal course of dosage administration.
- the container or pouch is provided with an amount of an anti- abuse substance normally in the form of a binding agent selected for use with the particular abusable substance contained in the patch and is located in the container or pouch.
- a closure device for closing the container or pouch is also provided so that the container can also provide a closed system for disposing of the used skin-worn patch.
- the closure system may include an adhesive seal or zip lock to seal the patch in the container.
- a layer of absorbent material such as activated carbon is provided in the patch itself separated from the layer containing the active ingredient by a lightly adhering separation membrane. The separation membrane remains in place during the initial application and wearing of the patch but is provided with an extension or connecting section which includes an amount of adhesive near the end and which adhesively adheres to the skin of the patient at the time the patch is applied.
- the extension or connecting device to pull on and remove the separator membrane from between the layer of anti-abuse substance or absorbent material and the layer containing the active ingredient as the patch is removed from the patient so that the two are brought into contact and the remaining active ingredient is immobilized or absorbed by the binding agent or absorbent, thereby rendering the remaining dosage harmless.
- a binding agent such as activated carbon
- a binding agent can prevent users from recovering drugs with use of commonly available solvents such as water, ethanol and mixtures thereof.
- an antagonist for an abusable substance is a compound or composition which acts upon or affects the user to essentially diminish or prevent the pharmacological effects of the abusable subject or greatly delays such affects.
- an irritant refers to any substance that causes inflammation following immediate, prolonged, or repeated contact with skin or mucous membranes .
- suitable protection agents include, without limitation, naloxone or naltrexone as antagonists and capsaicin or epicac as irritants .
- An advantage of this approach as compared to prior concepts such as that of U.S. Patent 5,236,714, cited above, is that the antagonist and/or irritant layer is designed to be kept separated from the drug during storage and wear periods, thereby presenting an advantage from a shelf life stability perspective.
- Figure 1 is a simplified schematic view of one embodiment of the invention showing a patch and container system with parts omitted for clarity;
- Figures 2a and 2b are simplified schematic drawings that depict an alternate embodiment of the abuse potential reducing system of the invention;
- Figure 3 is a plot showing a UV/VIS spectrophotometry scan of a 37.7 mg/1 solution of fentanyl citrate showing absorption from 200-240 nm;
- Figure 4 is a UV/VIS spectrophotometry scan plot of the solution of Figure 3, after 5 minutes of contact with activated carbon;
- Figure 5 is a UV/VIS spectrophotometry scan plot of a 50% ethanol solution utilized to attempt to extract adsorbed fentanyl citrate from the activated carbon used to adsorb the fentanyl citrate in Figure 4.
- FIG. 1 depicts a skin-worn patch 10 of a class utilized with transdermal delivery of an abusable substance such as an opioid.
- the patch is depicted generally by 10 and includes a skin fastening adhesive-containing layer 12 and an opioid-containing layer designed to contact the skin at 14.
- a disposal container or pouch designed to accompany the skin-worn patch 10 is shown generally by the reference character 16 and includes a layer of absorbent material 18 attached to one side of the container 16 in the manner such that insertion of the used skin-worn patch 10 as is shown by the arrow 20 with the opioid layer 14 facing the adsorptive material 18, ensures that contact will occur between the layers 14 and 18, thereby adsorbing and deactivating the opioid from layer 14.
- the container 16 is also provided with a means of sealing the patch 14 inside such as exemplified by adhesive strips 22 on each side of the container. In this manner, the container 16 containing the used patch 14 may then be thrown away with the knowledge that the opioid material contained in the layer 14 of the skin-worn patch 10 has been successfully deactivated by the adsorptive material in the layer 18. In the case of opioids, this is preferably activated carbon.
- the second embodiment is shown in Figures 2a and 2b. Those drawings illustrate a simplified schematic representation of a skin-worn patch 30 for the transdermal delivery of a therapeutic drug material such as an opioid contained in a layer 32. A layer containing an amount of absorbent material, such as activated carbon, is shown at 34.
- the patch 30 is depicted as it would appear when applied to the skin of a patient and as it would appear during administration of the abusable substance to the patient.
- the patch is provided with a lightly adhering or releasable separation membrane 36 which separates the substance to be administered in layer 32 from the absorbent material in layer 34.
- the membrane 36 is attached to or is provided with an integrally formed connector shown at 38 which contains an amount of adhesive 40 which causes the connector 38 to adhere to the skin of a patient shown at 42.
- the normal patch adhesive overlayer which attaches the patch to the skin is shown at 44.
- Figure 2b depicts the patch 30 as it is being removed from the skin 42 of a patient.
- FIG. 3 depicts a plot of a UV/VIS spectrophotometry scan of a 37.7 mg/1 solution of fentanyl citrate. The absorption from 200-240 nm is due to the fentanyl citrate present in the solution, and the magnitude of the absorbance is directly related to the dissolved concentration of that compound. It is readily seen that the concentration of the drug is significant.
- Figure 4 represents a second UV/VIS spectrophotometry scan plot of the solution of Figure 3 after 5 minutes of contact with activated carbon. Note the dramatic reduction in the amount of absorption from 200-240 n . The data shows that an estimated 97% of the fentanyl citrate had been removed from solution by 5 minutes of contact with activated carbon. Only 11 micrograms from the original content of 377 micrograms of fentanyl citrate was remaining in solution. The activated carbon utilized to adsorb the fentanyl citrate from the solution of Figure 3 was then taken and placed in a 50% ethanol/water solution in an attempt to redissolve the adsorbed fentanyl citrate.
- the plot of Figure 5 represents another UV/VIS spectrophotometry scan of the 50% ethanol solution from which it appears that recovery of fentanyl citrate in the 50% ethanol solution was extremely low, i.e., less than 5% of the drug was recovered. This indicates that the adsorption of the drug onto the carbon was not only almost complete, but also very tenacious. Of the 366 micrograms of fentanyl citrate that was bound, only 13 micrograms was successfully separated in the attempted extraction process.
- the layer of absorbent material 18 in Figure 1 and the layer 34 of absorbent material in Figures 2a and 2b can be selectively provided with an antagonist and/or an irritant material that goes into solution with the opioid or other abusable drug of interest in order to provide further means of abuse protection.
- the antagonist and/or irritant compounds serve as added abuse resistance protection. It is also contemplated that under some circumstances antagonist and/or irritant compounds might replace the binding agent entirely as the active anti-abuse substance or ingredient of the layers 18 and 34 .
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Environmental & Geological Engineering (AREA)
- Emergency Management (AREA)
- Business, Economics & Management (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mechanical Engineering (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05711945.5A EP1720498B8 (en) | 2004-01-23 | 2005-01-20 | Abuse potential reduction in abusable substance dosage form |
JP2006551380A JP4642784B2 (en) | 2004-01-23 | 2005-01-20 | Reduced abuse potential in dosage forms of abuseable substances |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/763,628 | 2004-01-23 | ||
US10/763,628 US7867511B2 (en) | 2004-01-23 | 2004-01-23 | Abuse potential reduction in abusable substance dosage form |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2005070003A2 true WO2005070003A2 (en) | 2005-08-04 |
WO2005070003A3 WO2005070003A3 (en) | 2006-01-05 |
WO2005070003B1 WO2005070003B1 (en) | 2006-04-27 |
Family
ID=34795082
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/002246 WO2005070003A2 (en) | 2004-01-23 | 2005-01-20 | Abuse potential reduction in abusable substance dosage form |
Country Status (4)
Country | Link |
---|---|
US (9) | US7867511B2 (en) |
EP (1) | EP1720498B8 (en) |
JP (2) | JP4642784B2 (en) |
WO (1) | WO2005070003A2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102006025282A1 (en) * | 2006-05-31 | 2007-12-20 | Lts Lohmann Therapie-Systeme Ag | Self-destructive transdermal therapeutic system |
DE202008004785U1 (en) * | 2008-04-04 | 2009-08-13 | Grünenthal GmbH | disposal device |
US9339856B2 (en) | 2011-09-30 | 2016-05-17 | Teikoku Pharma Usa, Inc. | Transdermal patch disposal system |
US10391346B2 (en) | 2004-01-23 | 2019-08-27 | Verde Environmental Technologies, Inc. | Abuse potential reduction in abusable substance dosage form |
US11389844B2 (en) | 2018-03-20 | 2022-07-19 | Verde Environmental Technologies, Inc. | Blister pack disposal system |
USD968640S1 (en) | 2018-12-27 | 2022-11-01 | Stryker Corporation | Pharmaceutical waste disposal assembly |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2266719B1 (en) * | 2001-04-23 | 2016-06-08 | Euro-Celtique S.A. | Disposal system for transdermal dosage form |
US7144587B2 (en) * | 2001-08-06 | 2006-12-05 | Euro-Celtique S.A. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent |
US7842307B2 (en) | 2001-08-06 | 2010-11-30 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent |
US7141250B2 (en) * | 2001-08-06 | 2006-11-28 | Euro-Celtique S.A. | Pharmaceutical formulation containing bittering agent |
US7157103B2 (en) | 2001-08-06 | 2007-01-02 | Euro-Celtique S.A. | Pharmaceutical formulation containing irritant |
US7332182B2 (en) | 2001-08-06 | 2008-02-19 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
US20030044458A1 (en) | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
US8535711B2 (en) * | 2004-01-23 | 2013-09-17 | Teikoku Pharma Usa, Inc. | Medication disposal system |
ES2653568T3 (en) | 2004-06-12 | 2018-02-07 | Collegium Pharmaceutical, Inc. | Drug formulations for abuse prevention |
US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
JP5254616B2 (en) | 2004-09-13 | 2013-08-07 | クロノ セラピューティクス、インコーポレイテッド | Biosynchronous transdermal drug delivery |
DE102006047270A1 (en) * | 2006-10-04 | 2008-04-10 | Grünenthal GmbH | disposal system |
WO2008115811A2 (en) * | 2007-03-16 | 2008-09-25 | Endo Pharmaceuticals, Inc. | Transdermal delivery form disposal systems and methods |
DE102008016804B4 (en) * | 2008-04-02 | 2012-01-05 | Lts Lohmann Therapie-Systeme Ag | Self-destructive transdermal therapeutic system with improved functionality and efficacy as well as its use |
US8236238B2 (en) | 2009-01-21 | 2012-08-07 | Palo Alto Research Center Incorporated | Drug deactivation system |
US7838715B2 (en) * | 2009-01-21 | 2010-11-23 | Palo Alto Research Center Incorporated | Drug deactivation system and method of deactivating a drug using the same |
KR101082589B1 (en) * | 2009-07-23 | 2011-11-10 | 한국과학기술원 | System for providing Aspect Level News Browsing Service that reduce Media-Bias Effect and Method therefor |
DE102009036485B4 (en) * | 2009-08-07 | 2012-10-04 | Lts Lohmann Therapie-Systeme Ag | Agent for the destructive disposal of medical active substances in transdermal therapeutic systems |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
US9046403B2 (en) * | 2010-02-01 | 2015-06-02 | Mallinckrodt Llc | Systems and methods for managing use of a medicament |
US8910456B2 (en) * | 2010-02-01 | 2014-12-16 | Mallinckrodt | Apparatuses and methods for storing pharmaceutical product |
US8925727B2 (en) | 2010-02-01 | 2015-01-06 | Mallinckrodt Llc | Disposable transdermal patch packaging |
US8490795B2 (en) * | 2010-02-01 | 2013-07-23 | Mallinckrodt Llc | Container and method for facilitating disposal of unused pharmaceutical product |
WO2012017228A1 (en) * | 2010-08-02 | 2012-02-09 | Archimedes Development Limited | Medicine disposal container |
EP2826469A1 (en) | 2010-12-22 | 2015-01-21 | Purdue Pharma L.P. | Encased tamper resistant controlled release dosage forms |
CA2822769C (en) | 2010-12-23 | 2016-10-04 | Purdue Pharma L.P. | Tamper resistant solid oral dosage forms |
EP2729148A4 (en) | 2011-07-06 | 2015-04-22 | Parkinson S Inst | Compositions and methods for treatment of symptoms in parkinson's disease patients |
KR20140067042A (en) * | 2011-09-30 | 2014-06-03 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | General medication disposal system |
US20130267915A1 (en) * | 2012-04-09 | 2013-10-10 | David Hoffman | Medical grade cleansing and numbing agent combination pad |
SG11201506064UA (en) | 2013-02-05 | 2015-08-28 | Purdue Pharma Lp | Tamper resistant pharmaceutical formulations |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
US10010543B1 (en) | 2014-12-23 | 2018-07-03 | Barr Laboratories, Inc. | Transdermal dosage form |
JP2018511355A (en) | 2015-01-28 | 2018-04-26 | クロノ セラピューティクス インコーポレイテッドChrono Therapeutics Inc. | Drug delivery method and system |
JP2018511127A (en) | 2015-03-12 | 2018-04-19 | クロノ セラピューティクス インコーポレイテッドChrono Therapeutics Inc. | Craving input and support system |
CA2907269C (en) * | 2015-10-07 | 2023-09-26 | Matthew Kennedy | Hollow light guide luminaire |
WO2017222575A1 (en) | 2016-06-23 | 2017-12-28 | Collegium Pharmaceutical, Inc. | Process of making more stable abuse-deterrent oral formulations |
CA2972220C (en) | 2016-06-29 | 2023-01-24 | Disposerx, Inc. | Disposal of medicaments |
US11058314B1 (en) | 2016-07-12 | 2021-07-13 | Mahesh M. Galgalikar | Remote individual monitoring, training and recording system |
US11285306B2 (en) | 2017-01-06 | 2022-03-29 | Morningside Venture Investments Limited | Transdermal drug delivery devices and methods |
US10898934B2 (en) | 2017-01-30 | 2021-01-26 | Kirti H. Valia | Drug disposal devices and methods of use |
US11446531B2 (en) | 2017-10-27 | 2022-09-20 | NarcX | Medication disposal solution |
JP7420797B2 (en) | 2018-05-29 | 2024-01-23 | モーニングサイド ベンチャー インベストメンツ リミテッド | Drug delivery methods and systems |
USD989303S1 (en) | 2019-12-12 | 2023-06-13 | Stryker Corporation | Pharmaceutical waste disposal assembly |
CA3121058A1 (en) * | 2021-03-17 | 2022-09-17 | Ai-Genetika Inc., Doing Business As Biotwin | Method of using digital twin biomarker profiles for improved sports training and performance, wellness and healthcare outcomes |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4909256A (en) | 1985-02-11 | 1990-03-20 | The United States Of America, As Represented By The Secretary Of The Army | Transdermal vapor collection method and apparatus |
US5396901A (en) | 1994-01-11 | 1995-03-14 | Phillips; Michael | Transdermal dosimeter device |
WO2002007482A2 (en) | 2000-07-18 | 2002-01-24 | General Electric Company | Micro electro mechanical system controlled organic led and pixel arrays and method of using and of manufacturing same |
WO2003103673A1 (en) | 2002-06-10 | 2003-12-18 | Purdue Pharma, L.P. | Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein |
US20040013716A1 (en) | 2002-04-23 | 2004-01-22 | Gale Robert M. | Transdermal analgesic systems with reduced abuse potential |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1781314A (en) | 1926-03-29 | 1930-11-11 | Darco Corp | Water purification |
JPS49130472U (en) | 1973-03-06 | 1974-11-08 | ||
US4116649A (en) * | 1976-01-16 | 1978-09-26 | Multiform Desiccant Products, Inc. | Self-retaining adsorbent bag unit |
US4588580B2 (en) * | 1984-07-23 | 1999-02-16 | Alaz Corp | Transdermal administration of fentanyl and device therefor |
JPS61171537A (en) | 1985-01-24 | 1986-08-02 | Shigekazu Nakano | Gel-like adsorbent |
US4605499A (en) | 1985-02-19 | 1986-08-12 | WISE Lawrence | Water filter |
JPH0725689B2 (en) | 1986-10-07 | 1995-03-22 | 中外製薬株式会社 | Sustained-release preparation containing granulocyte colony-stimulating factor |
GB8715421D0 (en) | 1987-07-01 | 1987-08-05 | Charcoal Cloth Ltd | Wound dressing |
US4830643A (en) | 1988-07-13 | 1989-05-16 | W. L. Gore & Associates, Inc. | Expanded polytetrafluoroethylene tubular container |
US5899856A (en) * | 1988-09-08 | 1999-05-04 | Sudormed, Inc. | Dermal patch detecting long-term alcohol consumption and method of use |
US5465713A (en) | 1988-09-08 | 1995-11-14 | Sudor Partners | Energy-assisted transdermal collection patch for accelerated analyte collection and method of use |
JPH0285182A (en) | 1988-09-09 | 1990-03-26 | Hagiwara Kogyo Kk | Deodorizing and freshness keeping bag |
US5236714A (en) * | 1988-11-01 | 1993-08-17 | Alza Corporation | Abusable substance dosage form having reduced abuse potential |
JP2575207B2 (en) * | 1989-01-20 | 1997-01-22 | 積水化学工業株式会社 | Medical patch |
US5019254A (en) | 1989-08-16 | 1991-05-28 | Aquarium Pharmaceuticals, Inc. | Filter pad with pocket and method of using the same |
US5022553A (en) | 1990-05-29 | 1991-06-11 | Pontius Jeffrey S | Temporary diaper storage container |
US5149538A (en) * | 1991-06-14 | 1992-09-22 | Warner-Lambert Company | Misuse-resistive transdermal opioid dosage form |
US5174462A (en) | 1991-10-17 | 1992-12-29 | John M. Norton | Adsorbent neutralizer |
US5259499A (en) | 1992-12-10 | 1993-11-09 | St. Francis Research Institute | System and apparatus for accurate drug inventory control |
US5451444A (en) * | 1993-01-29 | 1995-09-19 | Deliso; Evelyn M. | Carbon-coated inorganic substrates |
DE69429337T3 (en) * | 1993-04-02 | 2012-08-30 | Anticancer Inc. | METHOD FOR THE ADMINISTRATION OF SPATIAL COMPOSITIONS TO HAIR FOLLICLES |
AU1098495A (en) | 1993-11-30 | 1995-06-19 | Reckitt & Colman Inc. | Refrigerator freshener |
JP3588835B2 (en) | 1994-12-12 | 2004-11-17 | 東洋紡績株式会社 | Container type filter |
JPH08229140A (en) * | 1995-02-28 | 1996-09-10 | Hisamitsu Pharmaceut Co Inc | Device for iontophoresis |
US6279736B1 (en) * | 1995-04-19 | 2001-08-28 | Capitol Specialty Plastics, Inc. | Barrier pack having an absorbing agent applied to the interior of the pack |
JP3172395B2 (en) * | 1995-06-14 | 2001-06-04 | 科学技術振興事業団 | Transdermal drug release device |
JPH0965784A (en) | 1995-09-01 | 1997-03-11 | Unitika Ltd | Water culture and container therefor |
JPH09201420A (en) * | 1996-01-30 | 1997-08-05 | Hisamitsu Pharmaceut Co Inc | Device for iontophoresis being active on use |
US5804215A (en) * | 1997-03-21 | 1998-09-08 | L. Perrigo Company | Transdermal patch disposal system and method |
US6262595B1 (en) * | 1997-06-10 | 2001-07-17 | Altera Corporation | High-speed programmable interconnect |
US7011843B2 (en) * | 1997-10-01 | 2006-03-14 | Lts Lohmann-Therapie Systeme Ag | Method for protecting a human being against health impairment by ingestion of a transdermal therapeutic system |
DE19743484C1 (en) * | 1997-10-01 | 1999-01-28 | Lohmann Therapie Syst Lts | Transdermal patches containing substance with unpleasant taste |
US6024012A (en) | 1998-02-02 | 2000-02-15 | World Drink Usa, L.L.P. | Porous plastic dispensing article |
JPH11276887A (en) | 1998-03-27 | 1999-10-12 | 饒 ▲斉▼藤 | Absorbing material and absorbing base material for oil |
ES2200577T3 (en) | 1998-11-16 | 2004-03-01 | THE PROCTER & GAMBLE COMPANY | GARBAGE BAGS THAT NEUTRALIZE ODOR AND ABSORB LIQUIDS. |
JP2000206111A (en) | 1999-01-20 | 2000-07-28 | Sekisui Chem Co Ltd | Packaging container for vacuum blood-collecting tube |
JP2000281566A (en) * | 1999-01-28 | 2000-10-10 | Yuutoku Yakuhin Kogyo Kk | Improved time control system for drug releasing of percutaneous preparation |
JP2001000774A (en) | 1999-06-21 | 2001-01-09 | Hinomaru Carbo Techno Kk | Purifier for washing machine |
US6660901B2 (en) * | 1999-09-24 | 2003-12-09 | Glenda Church | Charcoal skin patch |
US6261595B1 (en) * | 2000-02-29 | 2001-07-17 | Zars, Inc. | Transdermal drug patch with attached pocket for controlled heating device |
JP2001348577A (en) | 2000-06-06 | 2001-12-18 | Yakata Kk | Method for keeping quality of pyroligneous acid or bamboo pyroligneous acid, and adding active ingredient |
GB0026137D0 (en) * | 2000-10-25 | 2000-12-13 | Euro Celtique Sa | Transdermal dosage form |
US6475513B1 (en) | 2001-04-09 | 2002-11-05 | Kiyoshi Yamada | Skin-care pouch |
EP2266719B1 (en) * | 2001-04-23 | 2016-06-08 | Euro-Celtique S.A. | Disposal system for transdermal dosage form |
JP5296284B2 (en) | 2001-05-01 | 2013-09-25 | ユーロ−セルティーク エス・エイ | Abuse-preventing opioid-containing percutaneous system |
US6797857B2 (en) | 2001-05-24 | 2004-09-28 | Deroyal Industries | Solidifier for a liquid |
US20030078552A1 (en) | 2001-06-01 | 2003-04-24 | The Procter & Gamble Company | Odor-controlling disposal container |
US7332182B2 (en) * | 2001-08-06 | 2008-02-19 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant |
EP1423334A4 (en) | 2001-08-10 | 2007-09-26 | Innova Pure Water Inc | Hollow fiber membrane filters in various containers |
JP2003104875A (en) * | 2001-09-28 | 2003-04-09 | Yuutoku Yakuhin Kogyo Kk | Device for slow release medicine |
JP3097492U (en) | 2002-02-04 | 2004-01-29 | 楠野 弦 | Article storage bag having a cut groove at the opening |
US20040033253A1 (en) * | 2002-02-19 | 2004-02-19 | Ihor Shevchuk | Acyl opioid antagonists |
US20060110080A1 (en) * | 2002-02-27 | 2006-05-25 | Thomas Toby R | Packages and structures with selective dosing of active agent |
PT1530469E (en) * | 2002-08-20 | 2009-05-19 | Euro Celtique Sa | Transdermal dosage form comprising an active agent and a salt and free-base form of an antagonist |
US20040109886A1 (en) | 2002-08-27 | 2004-06-10 | Larry Rigby | Methods and apparatus for transdermal delivery of abusable drugs with a deterrent agent |
US8524272B2 (en) | 2003-08-15 | 2013-09-03 | Mylan Technologies, Inc. | Transdermal patch incorporating active agent migration barrier layer |
US7361184B2 (en) | 2003-09-08 | 2008-04-22 | Joshi Ashok V | Device and method for wound therapy |
US7275645B2 (en) * | 2003-09-19 | 2007-10-02 | Vesta Medical, Llc | Handheld medical waste sorting device |
AU2006225241B2 (en) | 2003-09-24 | 2008-07-17 | Tianda Pharmaceuticals (Australia) Pty Limited | Medication Holder |
US20050112068A1 (en) * | 2003-10-28 | 2005-05-26 | Warner Kevin S. | Systems and methods for reducing unintended use of active ingredients in dermal delivery devices |
US20050177119A1 (en) | 2004-01-21 | 2005-08-11 | Tsai M. L. | Pouch for medical use |
US7867511B2 (en) * | 2004-01-23 | 2011-01-11 | Travanti Pharma Inc. | Abuse potential reduction in abusable substance dosage form |
US8535711B2 (en) | 2004-01-23 | 2013-09-17 | Teikoku Pharma Usa, Inc. | Medication disposal system |
US20050211099A1 (en) | 2004-03-23 | 2005-09-29 | Doughty David T | Spiral composite adsorbent material |
US7704598B2 (en) | 2004-05-26 | 2010-04-27 | Gore Enterprise Holdings, Inc. | Durable covering for chemical protection |
ITMI20041332A1 (en) | 2004-07-01 | 2004-10-01 | N G G Medical S P A | STRUCTURE OF DISPOSABLE RIGID CONTAINER PARTICULARLY FOR THE COLLECTION OF CONTAMINATED SANITARY LIQUIDS FOR THEIR DISPOSAL IN SEMI-SOLID FORM |
GB2432529B (en) | 2005-11-25 | 2008-04-23 | Univ Feng Chia | Antimicrobial compositions and wound dressings |
US7431863B2 (en) | 2006-03-08 | 2008-10-07 | Ppg Industries Ohio, Inc. | Calcium hypochlorite composition |
US20080019618A1 (en) * | 2006-05-01 | 2008-01-24 | Dayton Douglas C | Systems and methods for a resealable waste disposal bag |
JP2008043237A (en) | 2006-08-11 | 2008-02-28 | Kao Corp | Packaged coffee beverage |
JP4994138B2 (en) | 2007-07-18 | 2012-08-08 | 株式会社生産日本社 | Bag opening tape and packaging bag |
EP2178486A2 (en) | 2007-08-09 | 2010-04-28 | Ranbaxy Laboratories Limited | Packaging kit for statins and compositions thereof |
US7918776B2 (en) * | 2007-11-19 | 2011-04-05 | Sherry Day | Composition for disposing of unused medicines |
US8785712B2 (en) | 2009-06-12 | 2014-07-22 | Rx Disposal Solutions, Llc | Pharmaceutical drug disposal kit |
WO2012017228A1 (en) | 2010-08-02 | 2012-02-09 | Archimedes Development Limited | Medicine disposal container |
US9045353B2 (en) | 2010-09-04 | 2015-06-02 | Hydros Bottle, Llc | Filtering water bottle |
KR20140067042A (en) | 2011-09-30 | 2014-06-03 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | General medication disposal system |
JP5964435B2 (en) | 2011-09-30 | 2016-08-03 | テイコク ファーマ ユーエスエー インコーポレーテッド | Transdermal patch disposal system |
-
2004
- 2004-01-23 US US10/763,628 patent/US7867511B2/en active Active
-
2005
- 2005-01-20 EP EP05711945.5A patent/EP1720498B8/en active Active
- 2005-01-20 WO PCT/US2005/002246 patent/WO2005070003A2/en active Application Filing
- 2005-01-20 JP JP2006551380A patent/JP4642784B2/en active Active
-
2009
- 2009-11-19 US US12/621,619 patent/US8329212B2/en active Active
-
2010
- 2010-07-09 JP JP2010156607A patent/JP5248555B2/en active Active
- 2010-11-23 US US12/952,516 patent/US8475837B2/en not_active Expired - Lifetime
- 2010-12-22 US US12/976,610 patent/US8445010B2/en not_active Expired - Lifetime
-
2013
- 2013-04-22 US US13/867,510 patent/US10391346B2/en active Active
-
2015
- 2015-08-17 US US14/828,005 patent/US10406394B2/en active Active
- 2015-08-17 US US14/827,998 patent/US10413768B2/en active Active
-
2018
- 2018-02-27 US US15/907,059 patent/US20180185686A1/en not_active Abandoned
-
2020
- 2020-05-29 US US16/887,921 patent/US11305144B2/en not_active Expired - Lifetime
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4909256A (en) | 1985-02-11 | 1990-03-20 | The United States Of America, As Represented By The Secretary Of The Army | Transdermal vapor collection method and apparatus |
US5396901A (en) | 1994-01-11 | 1995-03-14 | Phillips; Michael | Transdermal dosimeter device |
WO2002007482A2 (en) | 2000-07-18 | 2002-01-24 | General Electric Company | Micro electro mechanical system controlled organic led and pixel arrays and method of using and of manufacturing same |
US20040013716A1 (en) | 2002-04-23 | 2004-01-22 | Gale Robert M. | Transdermal analgesic systems with reduced abuse potential |
WO2003103673A1 (en) | 2002-06-10 | 2003-12-18 | Purdue Pharma, L.P. | Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein |
Non-Patent Citations (1)
Title |
---|
See also references of EP1720498A4 |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10391346B2 (en) | 2004-01-23 | 2019-08-27 | Verde Environmental Technologies, Inc. | Abuse potential reduction in abusable substance dosage form |
US11305144B2 (en) | 2004-01-23 | 2022-04-19 | Verde Environmental Technologies, Inc. | Abuse potential reduction in abusable substance dosage form |
US10413768B2 (en) | 2004-01-23 | 2019-09-17 | Verde Environmental Technologies, Inc. | Abuse potential reduction in abusable substance dosage form |
US10406394B2 (en) | 2004-01-23 | 2019-09-10 | Verde Environmental Technologies, Inc. | Abuse potential reduction in abusable substance dosage form |
US8075912B2 (en) | 2006-05-31 | 2011-12-13 | Lts Lohmann Therapie-Systeme Ag | Autodestructive transdermal therapeutic system |
EP2907510A1 (en) | 2006-05-31 | 2015-08-19 | LTS Lohmann Therapie-Systeme AG | Autodestructive transdermal therapeutic system |
JP2014055162A (en) * | 2006-05-31 | 2014-03-27 | Lts Lohmann Therapie-Systeme Ag | Autodestructive transdermal therapeutic system |
DE102006025282A1 (en) * | 2006-05-31 | 2007-12-20 | Lts Lohmann Therapie-Systeme Ag | Self-destructive transdermal therapeutic system |
JP2009538842A (en) * | 2006-05-31 | 2009-11-12 | エルテーエス ローマン テラピー−ジステーメ アーゲー | Self-destructive transdermal therapeutic system |
DE202008004785U1 (en) * | 2008-04-04 | 2009-08-13 | Grünenthal GmbH | disposal device |
US9339856B2 (en) | 2011-09-30 | 2016-05-17 | Teikoku Pharma Usa, Inc. | Transdermal patch disposal system |
US11389844B2 (en) | 2018-03-20 | 2022-07-19 | Verde Environmental Technologies, Inc. | Blister pack disposal system |
US11883865B2 (en) | 2018-03-20 | 2024-01-30 | Verde Environmental Technologies, Inc. | Blister pack disposal system |
USD968640S1 (en) | 2018-12-27 | 2022-11-01 | Stryker Corporation | Pharmaceutical waste disposal assembly |
Also Published As
Publication number | Publication date |
---|---|
US20150352011A1 (en) | 2015-12-10 |
US20050163717A1 (en) | 2005-07-28 |
US20130233748A1 (en) | 2013-09-12 |
US20200289863A1 (en) | 2020-09-17 |
JP5248555B2 (en) | 2013-07-31 |
EP1720498B1 (en) | 2016-09-21 |
EP1720498A4 (en) | 2012-08-22 |
JP4642784B2 (en) | 2011-03-02 |
EP1720498B8 (en) | 2016-11-09 |
US8475837B2 (en) | 2013-07-02 |
US20100068250A1 (en) | 2010-03-18 |
US11305144B2 (en) | 2022-04-19 |
US20110092926A1 (en) | 2011-04-21 |
US10406394B2 (en) | 2019-09-10 |
JP2007518819A (en) | 2007-07-12 |
US8445010B2 (en) | 2013-05-21 |
US10391346B2 (en) | 2019-08-27 |
WO2005070003A3 (en) | 2006-01-05 |
US8329212B2 (en) | 2012-12-11 |
US10413768B2 (en) | 2019-09-17 |
EP1720498A2 (en) | 2006-11-15 |
US7867511B2 (en) | 2011-01-11 |
US20180185686A1 (en) | 2018-07-05 |
US20150352390A1 (en) | 2015-12-10 |
US20110066130A1 (en) | 2011-03-17 |
JP2010248238A (en) | 2010-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11305144B2 (en) | Abuse potential reduction in abusable substance dosage form | |
CA2754215C (en) | Medication disposal system | |
WO2005070003B1 (en) | Abuse potential reduction in abusable substance dosage form | |
PT1513532E (en) | Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein | |
US20050112068A1 (en) | Systems and methods for reducing unintended use of active ingredients in dermal delivery devices | |
MX2008015276A (en) | Autodestructive transdermal therapeutic system. | |
AU759609B2 (en) | Method for preventing the misuse of a transdermal therapeutic system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
B | Later publication of amended claims |
Effective date: 20060106 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006551380 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2005711945 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005711945 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 2005711945 Country of ref document: EP |